Key result
Combination therapy with lercanidipine 20 mg and enalapril 20 mg significantly reduced office diastolic blood pressure by 15.2 mmHg compared to an 8.8 mmHg reduction with placebo (p<0.001).
Why the study?
The fixed dose combination of lercanidipine and enalapril is quite new for Ukrainian physicians, warranting a review of its efficacy and safety evidence base.
Does the fixed dose combination of lercanidipine and enalapril safely reduce blood pressure in patients with moderate hypertension?
Does the fixed dose combination of lercanidipine and enalapril safely reduce blood pressure in patients with moderate hypertension?
Absolute Event Rate: -15.2% vs -8.8%
p-value: p=<0.001
The fixed-dose combination of lercanidipine and enalapril is an effective and safe option for blood pressure control in patients with moderate hypertension, including those with comorbidities.
In order to improve the effectiveness of antihypertensive treatment, doctors more often prescribe fixed dose combinations of two or three antihypertensive products. In this case, the concomitant effects of these products contribute to better control of blood pressure, improve patient’s adherence to treatment and reduce the risk of side effects. The fixed dose combination of lercanidipine and enalapril is quite new for Ukrainian physicians; however, there is already a sufficient evidence base for the efficacy and safety of such combination therapy. Lecranidipine – enalapril combination reduce systolic and diastolic blood pressure in patients with moderate hypertension without severe side effects. In addition, this combination is effective and safe in patients with comorbidities.
No takes yet. Share an insight, caveat, or question.
O. М. Barna (2021) conducted a review in Hypertension (n=1,039). Lercanidipine and Enalapril combination vs. Placebo was evaluated on Change in office diastolic blood pressure (DBP) from baseline (p=<0.001). Combination therapy with lercanidipine 20 mg and enalapril 20 mg significantly reduced office diastolic blood pressure by 15.2 mmHg compared to an 8.8 mmHg reduction with placebo (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: